Skip to content Skip to sidebar Skip to footer

Newsletter

Nick Sundich

1,217 articles published

Consumer

A year since joining Tabcorp, ex-AFL boss Gillon McLachlan improved the stock’s formerly dwindling odds

When we last wrote about Tabcorp (ASX: TAH) in June 2024, we said that,' it had been through a dog of a year, with its share price dropping roughly 40% in the last 12 months'. The company faced intense competition from online players, has fought off takeover attempts, merged with Tatts Group then demerged its lotteries…

ByNick SundichAugust 27, 20250Comments

Biotech Stocks Healthcare Stocks Small Caps Stocks

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

Think of 'America First' ASX stocks and Island Pharmaceuticals (ASX:ILA) typically hasn't come to mind, but its acquisition of Galidesivir should put it firmly in the list. You cannot question the data that the company is in possession of, but some investors may think a company with plans to undertake an 'animal study' is years…

ByNick SundichAugust 27, 20250Comments

Large Caps Tech Stocks Technology Uncategorized

WiseTech caps off a volatile FY25 with a post-results sell off, but what’s next

What a volatile FY25 it as for WiseTech. Just look at all that it went through: Richard White was going to depart, but he ultimately prevailed over his enemies, The company unveiled one of the biggest buys in its history, only to see customers of its target company not like the deal, Shares…

ByNick SundichAugust 27, 20250Comments

Healthcare Stocks Life Sciences Small Caps Stocks

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Nova Eye Medical (ASX:EYE) is no clinical stage medtech company, but has just an exciting 12 months ahead as if it was a clinical stage company with company-making catalysts ahead. Because even though it has commercialised its devices, a major 12 months are ahead during which it is expected to make major inroads in the US…

ByNick SundichAugust 27, 20250Comments

Healthcare Stocks Life Sciences

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug for a condition known as Focal Segmental Glomerulosclerosis (FSGS). For patients with FSGS, the kidneys’ ability to purify (clean) the blood is impaired. This can…

ByNick SundichAugust 27, 20250Comments

Blue Chip Stocks Consumer Large Caps

Skycity Entertainment Group (ASX:SKC): Is it on the same fatal path as Star Entertainment?

Is Skycity Entertainment Group (ASX:SKC) on the same path as Star? On one hand, it may sound preposterous as it has revenues just about the same as it was pre-COVID and it is profitable. The other, it announced a $240m capital raising the same day as its annual results and is seeing customers spend less…

ByNick SundichAugust 26, 20250Comments

Bank Stocks Basic Materials Blue Chip Stocks Consumer Copper Stocks Dividend Stocks Education Stocks Energy Stocks ETF General Gold Stocks Graphite Stocks Industrials Large Caps Life Sciences Lithium Stocks Mining Stocks Oil and Gas Stocks Palladium Stocks Property Real Estate Resources Safe Stocks Semiconductor stocks Small Caps Stocks Steel Stocks Tech Stocks Technology Telecommunications Stocks Travel Stocks Undervalued Stocks Uranium Stocks

6 of the best annual results on the ASX in FY25 and 6 of the worst!

Each reporting season, we like to recap some of the best annual results on the ASX and some of the worst as well. Amidst all the companies, it is easy for investors to get lost amidst the mire of information. And so we like to single out particular companies that impressed and others that did…

ByNick SundichAugust 26, 20250Comments

Healthcare Stocks

4 reasons why Pro Medicus (ASX:PME) just keeps rising to new heights

Another reporting season, another impressive result from Pro Medicus (ASX:PME). Eerily similar to the debate going on about CBA (ASX:CBA), investors debate about whether or not it is overvalued or undervalued, but the share price just keeps going up. We are not going to state our view on where it is headed next, although we…

ByNick SundichAugust 25, 20250Comments

Tech Stocks Technology

Graphics Processing Units (GPUs) made Nvidia and its investors a fortune, but why are they important and are there other stocks in that space?

10-15 years only ago, only professional techheads would know what Graphics Processing Units (GPUs) are, but everyone does now. In this article, we'll look at what they are, how they made Nvidia a fortune and other players in the space. What are the Best ASX AI Stocks to invest in right now? Check our buy/sell tips What…

ByNick SundichAugust 25, 20250Comments

Blue Chip Stocks Consumer Large Caps Retail Safe Stocks

Breville (ASX:BRG): Will consumer demand for $4500 coffee machines offset the impact of Trump’s tariffs?

Breville (ASX:BRG) is one of those consumer stocks caught in the crosshairs of Trump's tariffs and fell 30% in 2 months earlier in 2025. But its most recent annual results have given hope that customers may be willing to pay a premium for its goods. What are the Best ASX Consumer Stocks to invest in right…

ByNick SundichAugust 25, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Nick Sundich

A year since joining Tabcorp, ex-AFL boss Gillon McLachlan improved the stock’s formerly dwindling odds

Galidesivir has made Island Pharmaceuticals the ultimate ‘America First’ play for ASX investors!

WiseTech caps off a volatile FY25 with a post-results sell off, but what’s next

Nova Eye Medical (ASX:EYE) has been on a strong run, up 50% in one month. Is there more upside?

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Skycity Entertainment Group (ASX:SKC): Is it on the same fatal path as Star Entertainment?

6 of the best annual results on the ASX in FY25 and 6 of the worst!

4 reasons why Pro Medicus (ASX:PME) just keeps rising to new heights

Graphics Processing Units (GPUs) made Nvidia and its investors a fortune, but why are they important and are there other stocks in that space?

Breville (ASX:BRG): Will consumer demand for $4500 coffee machines offset the impact of Trump’s tariffs?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Nick Sundich

Add Your Heading Text Here